News

Featured Articles

Cristalia products with Nemera’s reusable pen injector commercialized in Brazil.

Cristalia’s human growth hormone will be administered with CRISPEN®. Approved by ANVISA1, CRISPEN® is part of Nemera’s state-of-the-art pen injector platform PENDURA AD.

2023

Nemera’s brand-new careers page goes live!

06/07/2023

We’re thrilled to announce the go-live of our brand-new careers page.

2023

SBTi approves Nemera’s near-term science-based emissions reduction target

16/05/2023

Last year in January, we announced our commitment to set near- and long-term company-wide emission reductions in line with science-based net-zero with the SBTi.

2023

Nemera and Nelson Labs Europe strengthen partnership to offer integrated services to customers

14/03/2023

This strategic alliance will give a unique advantage to pharmaceutical & bio-tech customers...

2023 ESG

Nemera reinforces commitment to sustainability with first integrated ESG report

10/03/2023

Designed as a snapshot of work over the years and a look into the future, the first ESG report is a new and important step forward in our sustainability journey...

2023 ESG

The Gender Equality Index at Nemera – Year 2022

28/02/2023

The Index, is calculated from 4 to 5 indicators depending on whether the company has less or more than 250 employees and takes into account

2023

Reinforcing Diversity & Inclusion and ESG strategies!

14/02/2023

It is critical to partner with local organizations to ensure everyone in our society has an equal chance to benefit from work opportunities and succeed professionally.